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The aim of the present studies was to evaluate the biodistribution of 
boronophenilalanina (10BPA) for the potential application of BNCT for the treatment of 
melanoma on an individual basis. A significant correlation between tumor temperature 
and tumor-to-blood (T/B) boron concentration ratio was found. A high number of 
positive cells for the proliferation marker Ki-67 and blood vessels of large diameter 
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Purpose: Patients with the same histopathological diagnosis of cutaneous melanoma 
treated with identical protocols of boron neutron capture therapy (BNCT), have shown 
different clinical outcomes. The objetive of the present studies was to evaluate the 
biodistribution of boronophenilalanina (10BPA) for the potential application of BNCT 
for the treatment of melanoma on an individual basis. Methods and Materials: The 
boronophenilalanine (BPA) uptake was evaluated in three human melanoma cell lines 
MEL-J, A375 and M8. NIH nude mice were implanted with 4 106 MEL-J cells and 
biodistribution studies of BPA (350mg/kg i.p ) were performed. Static Infrared Imaging 
(SIRI) utilizing a specially modified infrared camera adapted to measure the body 
infrared radiance of small animals, was employed. Proliferation marker, Ki-67 and 
endothelial marker, CD31, were analysed in tumor samples. Results: The in vitro 
studies demonstrated different patterns of boronophenilalanine (BPA) uptake for each 
analysed cell line (*** p < 0.001 for MEL-J and A375 vs. M8 cells). The in vivo studies 
showed a maximum average boron concentration of 25.9 ± 2.6 µg/g in tumor, with 
individual values ranging between 11.7 and 52.0 µg/g of 10B at 2 h post-injection of 
BPA. Tumor temperature always decreased as the tumors increased in size, with values 
ranging between 37 ºC and 23 ºC. A significant correlation between tumor temperature 
and tumor-to-blood boron concentration ratio was found (R-square=0.7, rational 
function fit). The immunohistochemical studies revealed, in tumors with extensive areas 
of viability, a high number of positive cells for Ki-67, blood vessels of large diameter 
evidenced by the marker CD31 and a direct logistic correlation between proliferative 
status and boron concentration difference between tumor and blood (R-square=0.81, 
logistic function fit). Conclusion: We propose that these methods could be suitable for 
designing new screening protocols applied prior to melanoma BNCT treatment for each 










Malignant melanoma is one of the most aggressive cancers in humans and is responsible 
for almost 60% of all lethal skin tumors. The incidence of melanoma has been 













between environmental (exogenous) and endogenous risk factors, in developing 
malignant melanoma. Usually it can be controlled with conventional or standard 
treatments if its detection occurs in the early stages of the disease. However, when the 
tumor is in an advanced stage, the effectiveness of these therapies is poor (1). 
  
Boron neutron capture therapy (BNCT) is considered a radiation therapy technique 
based on the selective uptake of a boron compound by tumoral tissue in comparison to 
surrounding normal tissue. Once the appropriated concentration of boron is achieved, 
the tumor is irradiated with a thermal or epithermal neutron beam. Following neutron 
capture, the unstable 11B nucleus immediately decays and releases an alpha particle and 
a 7Li nucleus. These high Linear Energy Transfer (LET) particles cause chromatin 
damage, difficult to repair and prone to create lethal lesions (2). At present, neutron 
sources for BNCT are currently limited to nuclear reactors, and clinical trials are being 
performed in several countries including Italy, Taiwan, Japan, Finland and Argentina 
for those malignancies that do not respond to standard therapies (3). 
  
Since the first applications, the clinical interest in BNCT has been focused on the 
treatment of high grade cutaneous melanoma. Mishima et al. had previously carried out 
extensive experimental studies using enriched 10B boronophenylalanine (BPA) (4). The 
first melanoma patients were treated in the USA in 1985 (5). Several other patients with 
either cutaneous or metastatic melanoma to the brain have been treated in other 
countries including Argentina (6, 7). All the results showed that BNCT seemed to be 














Histologically similar tumors may have different prognoses and may respond to the 
same therapy in different ways. It is believed that these differences in clinical behavior 
are related to molecular and structural differences between histologically similar tumors 
(8). At the present time, personalized medicine represents a new approach in the field of 
health care, that take into account the individual’s clinical, genomic and genetic 
characteristics and the environmental factors for each patient (9). This could enable a 
better approach to cancer treatment and could also have the potential to achieve 
measurable improvements in outcomes and a reduction on health care costs.  
 
In the present work we performed in vitro and in vivo analysis to evaluate the boron 
tumor incorporation for the potential application of BNCT for the treatment of 
cutaneous melanoma on an individual basis. In order to investigate the extent of this 
approach, the correlation between tumor boron uptake and different biological and 
physical parameters of the tumors was evaluated. Among the latter, and aiming at 
providing a non-invasive methodology for first-screening melanoma patients, we have 
employed Static Infrared Imaging (SIRI) utilizing a specially modified infrared camera 
adapted to measure the body infrared radiance of small animals, studying their body 
temperature distribution including normal, peritumoral and tumoral regions. 
 
2. Methods and Materials  
 
Cell lines 
The human melanoma cell line MEL-J, kindly provided by Dr. José Mordoh, Instituto 
de Investigaciones Bioquímicas Leloir (Buenos Aires, Argentina) (10), and the human 













fetal bovine serum (FBS), streptomycin (100 mg/ml) and penicillin (100 IU/ml). The 
human melanoma cell line A375 was cultured in DMEM/F12 medium supplemented 
with 10% FBS, streptomycin (100 mg/ml) and penicillin (100 IU/ml). Both cell lines 
were maintained at 37 °C in a humidified atmosphere containing 5% CO2. 
 
Animal model  
NIH nude mice, aged 6 to 8 weeks and weighing 20 to 25 g were implanted (s.c.) in the 
back right flank with 4x106 cells of the human melanoma cell line MEL-J. Animals 
were bred and maintained under aseptic conditions (11). 
 
Tumor growth measurement  
The size of the tumors was measured with a caliper twice a week and the volume was 




BPA-Fructose complex preparation  
The solution of L-p boronophenylalanine (BPA) (Gliconix Corp; Durham, US) was 
prepared at a concentration of 30 mg 10BPA per milliliter (0.14 M). Briefly, 10BPA 
(99% 10B-enriched) L-isomer, was combined in water with a 10% molar excess of 
fructose. The pH was adjusted to 9.5-10 with NaOH, the mixture was stirred until all 
















In vitro studies: Cells in exponential growth phase were used to determine the uptake of 
10B. The cells were incubated in 10 cm diameter petri dishes for 0.5, 2, 4 and 24 h with 
boronophenylalanine (BPA) (50 ppm 10B). At the end of the incubation with BPA the 
cells were washed three times with cold PBS, harvested with trypsin and centrifuged at 
900 x g. The number of cells was counted with a Neubauer’s chamber. BPA uptake was 
measured by inductively-coupled plasma optical emission spectroscopy (ICP-OES) and 
expressed as µg/g of tissue. 
 
Static Infrared Imaging 
Body temperature mapping of living subjects requires following standard procedures 
that aim at minimizing the influence of ambient and physiological factors which could 
interfere with the desired observations. Achieving normostatic conditions is a 
prerequisite for live screening and it is usually accomplished by controlling ambient 
temperature, infrared sources and unwanted stress of the subject of observation (14).  
The camera employed was a Raytheon PalmIR 250 (L3 Comm. Systems), which uses 
uncooled infrared ferroelectric sensors distributed in an array of 320x240 detectors, 
sensitive to infrared radiation in the 7-14 micrometers wavelength band. The original 
optics was modified from its original focus distance to observe targets located between 
0.5 m and 1 m. In this way, and focusing at 0.65 m, an angular field of view of 11°x8° 
and spatial resolution of 0.39 mm/pixel were achieved. Total temperature resolution, 
which comprises both the intrinsic sensitivity above noise and rounding by the analog-
to-digital conversion procedure, was about 0.3°C. The camera provides also an NTSC 
video signal that can be employed for studying temperature evolution (as needed in 















The infrared camera is routinely calibrated in temperature by reference black bodies. 
The assumed emissivity is 0.98 (a typical value for normal skin). To reduce changes in 
the mice homeostasis, the room is kept at a stable temperature, between 22 and 23 ºC. A 
set of 10 mice were examined with SIRI twice a week, during approximately 40 days 
after s.c. inoculation of tumor cells. For the studies, mice were held by hand without 
anesthesia and infrared videos were acquired for a few seconds in order to avoid the 
stressing influence of the immobilization procedure in the animal’s body temperature. 
Short videos were acquired for each mouse observing the right (inoculated side) and left 
flanks (normal side), and groin temperature was measured with a thermocouple as 
representative of body core temperature. All the SIRI studies were performed before 
BPA administration and animal sacrifice, thereby serving as an a priori non-invasive 
screening method. 
 
In vivo studies: To evaluate the BPA uptake, animals were injected with the boron 
compound at a dose of 350 mg/Kg b.w. (i.p.) and sacrificed at 0.5, 1, 2 and 3 h post-
administration. A total of 12 biodistribution studies were performed and 10 mice per 
group were used. For boron determination, tissue samples were always weighed before 
digestion. The tumor samples were divided into two pieces: one for boron measurement 
and the other for histological analysis. For histology and immunohistochemistry 
analyses, a rectangular band (300 x 6400 µm) in the sample preparation, which includes 















Digestion of tissue samples, with a mass range of 10-50 mg, was carried out for 2 h at 
60°C with 0.15 ml of a 1:1 mixture of concentrated nitric and sulfuric acids. Dilution to 
1.0 ml was performed with 0.65 ml of a 5% aqueous solution of Triton X-100 (v/v) and 
0.2 ml of a solution containing 25 µg/ml Sr and 0.5µg/ml Y as internal standards. Blood 
samples (200-300 µl) were digested for 2 h at the same temperature with 1.0 ml of the 
1:1 acid mixture and diluted to 5.0 ml with 3.0 ml of the Triton X-100 and 1.0 ml of the 
internal standard solution. Analytical and internal standard lines (in nm) were as 
follows: B: 249.677; Sr: 232.235; and Y: 371.029. Matrix matched standard solutions 
containing the internal standard elements and boron between 0.05 and 1.0 µg/ml were 
employed for daily calibration. 
 
Hematoxylin and Eosin (H&E) stains and immunohistochemistry 
Histological preparations were prepared from the tumor and the surrounding skin. 
Briefly, tissues were fixed with 10% buffered formol (pH 7.0) and paraffin embedded. 
Ten-micron-thick sections were cut and stained with H&E. All sections for 
immunohistochemistry were deparaffinized and rehydrated using graded concentrations 
of ethanol prepared with deionized water. The slides were transferred into a 0.05 M 
Tris-based solution in 0.15 M NaCl with 0.1% v/v Triton-X-100, pH 7.6 (TBST). 
Endogenous peroxidase was blocked with 3% hydrogen peroxide for 10 min. Antigen 
retrieval was done using microwave in citrate buffer at pH 6.0. All slides were 
incubated at room temperature for 1 h with one of two antibodies: rabbit polyclonal 
antibody against CD31, a validated endothelial marker (Abcam, Cambridge, UK) or 
monoclonal mouse anti-rat Ki-67, a marker of cell proliferation (DAKO, Ely, UK). 
Using a kidney and liver sections as controls, the highest titer of primary antibodies to 













staining was 1:50 for both anti CD31 and Ki-67. Negative controls were obtained by 
eliminating the primary antibodies from the diluents. After washing with PBS-Tween, 
biotinylated goat anti-rabbit IgG (1:1000; Cell Marque) was applied to the sections for 
30 minutes at room temperature. Sections were then incubated with Strepavidin -HRP 
(Sigma) for 30 minutes at room temperature. Diaminobenzide (DAB) was used as the 
cromagen and hematoxylin as the counterstain. Immunohistochemistry quantitation was 
performed by combining image and computerized microspectrophotometric analysis 
(15). Digital images were obtained from a single field of the preparation using a Zeiss 
MPM 400 microscope with an objective x 20/0, 75 a. Densitometric measurements were 
done with an image analysis program. The analysis was performed in 7 cases. The 
following parameters were evaluated in each case: total field area, number of Ki-67 or 
CD31 positive cells, integral optical density (IOD), optical density (OD) per pixel and 
viability and necrosis areas. Sections were mounted for examination. Stained slides 
were imaged at 0.25 µm per pixel resolution using a ScanScope XT.  
 
Statistical analysis 
All results (except temperature measurements, which comprise single observations) are 
expressed as the average of three independent experiments ± SEM. For statistical 
analysis of cell proliferation and biodistribution studies one way ANOVA followed by 
Bonferroni test were performed. Differences were considered significant when P < 0.05. 
 
3. Results 
The in vitro studies demonstrated different patterns of BPA uptake for each cell line. 
Figure 1 shows the cellular boron uptake in the three human melanoma cell lines (A375, 













increase in the intracellular boron concentration reaching a maximum value at 4 hours 
of incubation, with a non significant slight increase at 24 hours. On the other hand, the 
boron concentration did not show significant changes during the elapsed time of the 
study in the M8 cells. At 4 hours, the BPA average uptake was 0.119 ± 0.016 µg B/106 
cells for MEL-J, 0.109 ± 0.007 µg B/106 cells for A375 and 0.035 ± 0.007 µg B/106 
cells for M8 cells (*** P < 0.001 for MEL-J and A375 vs. M8 cells). The BPA uptake 
for MEL-J was 1.09 and 3.40 times higher than for A375 and M8, respectively, showing 
selectivity in the BPA uptake for this cell line. 
 
Table 1 show the results of the biodistribution of BPA at a dose of 350 mg/kg in NIH 
nude mice bearing melanoma. Tumor showed a maximum average BPA concentration 
of 25.9 ± 2.6 µg/g, with individual values ranging between 11.7 and 52.0 µg/g of 10B at 
2 h post-injection. Tumor-to-blood and tumor-to-distal skin ratios were 4.3 and 2.5, 
respectively.  
 
The average temperature of the left flank, determined by SIRI, was always around 37 
ºC, a value close to body core temperature, also measured independently by a 
thermocouple in the right groin. The temperature of the normal skin surrounding the 
tumor on the right flank (inoculated side) was usually higher (about 40 ºC) during the 
first two weeks after inoculation, and then approached 37-38 ºC after two weeks. 
Tumors started to be observed in the thermograhic studies around this point, and their 
temperature always decreased as the tumors increased in size, with values ranging 














Figure 2A shows the tumor temperature for each mouse measured in three separate days 
during the week previous to the biodistribution study, as a function of the later 
measured Tumor-to-Blood (T/B) ratios. Error bars are representative of the overall 
infrared camera accuracy (+ 0.3 ºC). A significant correlation between tumor 
temperature and T/B boron concentration ratio was found (R-square=0.7, rational 
function fit). Low temperature tumors, (usually tumors with a size of more than 1 
centimetre), are associated with low T/B ratios. Conversely, tumors with higher 
temperature (not necessarily small in size), are found to concentrate more 10B relative to 
blood. These findings can be better interpreted with the presentation of the data as 
shown in Figure 2B. Disregarding inflammation or metabolic heat sources, the 
difference between body core temperature (Tcore) and tumor temperature (Ttum), 
which represents the temperature drop through the tumor, is proportional to tumor 
thickness and inversely proportional to tumor heat conductivity. Thus, smaller tumors or 
tumors with higher heat conductivity (or both) would present smaller differences. In this 
study, tumors with smaller temperature differences are precisely those that accumulated 
more boron relative to blood. 
 
The histologic studies showed tumors with wide areas of viability (Fig. 3A) and 
variable number of small foci of necrosis (Fig. 3B). The percentage of viability area for 
each tumor sample was measured as a function of the boron uptake. Tumors with large 
areas of viability presented high boron uptake values (Fig. 3C).  
 
The immunohistochemical studies revealed, in tumors with extensive areas of viability, 
a high number of Ki-67-positive cells. Furthermore, we found tumor blood vessels of 













endothelial marker CD31. Figures 4A to D show two different samples: the case with 
the highest mark for both antibodies (Ki-67 and CD31) and the case with the lowest 
mark for both of them.  
 
In order to evaluate whether a direct correlation between proliferation status and BPA 
uptake exists, a non-dimensional quantity, computed as the scored number of Ki-67 
positive cells, times the average optical density (IOD) was constructed. This overall 
quantity, referred to as Proliferation Density (PD), was used as an independent variable 
and it was compared against the difference between boron concentration in tumor and 
blood boron concentration. The rationale for adopting the latter is as follows: in a very 
simplified tumor uptake model, it can be assumed that BPA reaches tumor cells first by 
passive diffusion and, depending on the cell metabolism, then it can be uptaken actively 
by those cells that are in the active state of the cell cycle (G1, S, G2, M), increasing 
further their boron concentration, but not by cells in quiescent state (G0, no 
proliferation). Following this idea, it is proposed that Ctum = Cblood + Cact, where Cact is 
the contribution to the total tumor concentration by active (proliferating) cells. 
 
Figure 5 shows the values of PD (in arbitrary units) and the corresponding Cact, using 
the minimum boron concentration, estimated after measuring around five to seven 
pieces in each tumor, as the value for Ctumor. The reason for choosing the minimum 
boron concentration in tumor is based on the fact that tumor control probabilities in the 
presence of non-uniform dose distributions (such as those typically observed in the 
BNCT clinical setting) are strongly influenced by the minimum rather than the average 
dose. A logistic curve with two free parameters and passing through (0,0) was employed 


















The usefulness of BNCT in the treatment of some types of malignant melanoma has 
convened a lot of multidisciplinary groups in order to optimize the outcome of this 
therapy in different research centers around the world. In our laboratory, and with the 
objective of improving the efficacy of BNCT for the treatment of melanoma, we have 
evaluated several physical, structural and histological parameters in an animal model, 
aiming at demonstrating the possibility of applying BNCT but considering individual 
patient’s characteristics. 
 
Standard radiotherapy shows different responses for the same kind of tumor (7). It has 
been observed that patients with the same histopathological diagnosis of cutaneous 
melanoma had different clinical outcomes to identical BNCT protocols (16). 
Interestingly, it has been observed that even tumors located in the same leg of one 
patient showed a different grade of response to the same treatment (6).     
 
There are different ways to optimize the BNCT treatment. The synthesis of new boron 
agents with more boron atoms per molecule or specific compounds for each kind of 
tumor is certainly one of them. Moreover, the development of new neutron sources and 
appropriate beams in accordance with tumor localization is a mode of improving the 
efficacy of BNCT. The use of radiosensitizing drugs in combination with the BNCT 













pathologies (17, 18). In this work, and in agreement with the new tendency of 
personalized oncology, we attempted to develop a series of different appropriate tests 
for the design of new screening protocols applicable prior to a BNCT treatment for each 
individual patient and lesion. As a first neccessary step, with this goal in mind, we 
evaluated the boronated amino acid (BPA) incorporation both in vitro as in vivo. After 
that, we performed predictive curves of tumoral uptake of BPA versus different physical 
and biological characteristics of each tumor. A previous estimation of the amount of 
boron in the tumor would allow optimization of the delivered treatment plan. 
 
In this study we demonstrated the differential kinetic uptake of BPA in three human 
melanoma cell lines. The BPA incorporation was higher for two of them (MEL-J and 
A375 vs. M8) and MEL-J cells showed the fastest uptake kinetic with a peak at 4 h after 
incubation other compared to A375 cells. Different intracellular boron concentrations 
for distinct cell lines of other tumor types were published as well (19, 20). 
 
The subsequent in vivo studies with one of the cell lines implanted into the flank of 
nude mice showed an exponential tumor growth after 25 days of implantation of 4 106 
cells reaching a volume of 930 mm3 (results not shown). The BPA biodistribution 
exhibited a peak of boron in the tumor at 2 h post-administration with individual values 
ranging between less than 12 ppm and no more than 52 ppm. In some animals the ratios 
were higher than 3, which is a generally accepted ratio for a therapeutic BNCT 
application. In others, the boron tissue ratios obtained were lower than 3. This is in 
agreement with other results published in different experimental studies. It is worth to 
note that, as in other animal models, the kidney has a high boron concentration, since it 













possible correlations between BPA uptake, temperature and the histological 
composition of the tumor sample. A direct correlation between tumor boron uptake and 
core-to-tumor temperature differences (a measure of heat flux across the tumor and 
tumor heat production) was observed. We also observed that tumors with small necrotic 
areas exhibited higher boron uptake and temperature than tumors with large necrotic 
regions.  
 
In xenograft models, generally, tumors grow very rapidly and their vasculature is 
significantly different from that of normal tissue. Tumor vessels are small, poorly 
organized, hyperpermeable and with impaired blood supply. All of these features 
contribute to reduce the tumor temperature (21). On the other hand in terms of material 
composition, soft tissues can be thought of as composed of mainly three physical 
materials: water, fat and protein. Among these, water is the material with the highest 
heat conductivity, being protein the worst conducting one. Thus, tumors with higher 
water content in the vascular, interstitial or stromal compartments will conduct heat 
more efficiently. Heat sources, as those originating from metabolism or inflammation, 
will always produce higher tumor temperatures (or, again, smaller differences relative to 
core temperature). Since they can be considered as additional factors that could play a 
positive role in boron uptake, they will affect the observed temperature in the same 
direction as decreasing tumor size and increasing water content (22). It is interesting to 
note that some studies have demonstrated that mouse tumor xenografts have a slightly 
lower temperature than the surrounding normal tissue as tumor grows (16). The same 














Thermal imaging has been used in clinical medicine since early 1960. This technique 
has been applied in the evaluation of patients suspected of having breast cancer, where 
an abnormal thermal pattern can be detected prior to clinical or mammographic 
changes. Also dynamic thermal imaging has been used intraoperatively during 
neurosurgical interventions (23). If our results were confirmed in human biodistribution 
studies for cutaneous melanoma, infrared thermography could provide a prospective 
tool for assessing non-invasively and beforehand the possible differences in boron 
tumor uptake and thus contribute to personalize a BNCT treatment plan. 
 
In immunohistochemical studies two different markers were analysed: Ki-67 and CD31. 
The Ki-67 protein is a cellular marker of proliferation that is presented in the cell in G1, 
S, G2 and mitosis cell cycle phases but it is absent in G0. Sometimes the degree of 
proliferative activity is considered to be one of the most important characteristics of 
malignant cutaneous melanoma when compared with benign melanocytic lesions (24, 
25). Our in vivo studies showed that Ki-67 could be an indicator of the degree of boron 
active incorporation in solid tumors. This fact is important not only to select a patient 
candidate for BNCT, but also to improve the clinical outcome of the therapy. Although 
more data would be needed to confirm both low and high proliferation density 
behaviour regarding active BPA uptake, the fact that a good fitting was obtained with a 
sigmoid curve that exhibits asymptotic trend for high proliferation values could indicate 
a possible saturation mechanism, with maximum achievable boron concentration values 
in tumor and, on the other hand, boron uptake similar to blood concentration values in 
quiescent cells. A similar correlation was found in the work of Coderre et al., analysing 
cell density and boron concentration (26). A quantity referred to as “cellularity index”, 













considered an estimate of the density of tumor cells. When plotted against boron 
concentration, the data exhibited a linear correlation that increased with the cellularity 
index of each particular sample. In the present work, an additional factor is considered, 
i.e., the Ki-67 staining intensity which, together with cell counting provides a more 
suitable index for the tumor proliferative state.  
  
In the case of CD31 staining, which is a specific marker of vascular endothelial cells, 
two different patterns were observed: tumors with a high number of large cross-section 
vessels and tumors with small vessels. The first type of tumors showed a higher boron 
uptake compared to the other type of tumors, with a smaller number of vessels. 
However, the importance of tumor vascularization for the prognosis of primary 
malignant melanomas of the skin remains controversial (27, 28). With these results 
obtained in an animal model of melanoma, we could suggest that tumors with larger 
blood supply also positively correlate with higher tumor temperatures.  
 
In summary, and in agreement with the personalized medicine, a new approach for 
optimizing the BNCT application is proposed. The main idea is to provide a treatment 
plan according to each patient's individual characteristics based on a priori knowledge 
of the genetic variation and specific characteristics of each patient tumor.   
 
Acknowledgments 

















1.  Bandarchi B, Jabbari CA, Vedadi A, Navab R. Molecular biology of normal 
melanocytes and melanoma cells. J Clin Pathol 2013; 66: 644-648. 
 
2. Barth RF, Coderre JA, Vicente MG, Blue TE. Boron neutron capture therapy of 
cancer: current status and future prospects. Clin Cancer Res 2005; 11: 3987-4002. 
 
3. Barth RF, Vicente MG, Harling OK, et al. Current status of boron neutron capture 
therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol 
2012;7:146.  
 
4. Mishima Y, Ichihashi M,, Hatta S, et al. New thermal neutron capture therapy for 
malignant melanoma: melanogenesis-seeking IOB molecule-melanoma cell interaction 
from in vitro to first clinical trial. Pigm Cell Res 1989; 2:226-234. 
 
5. Madoc-Jones H, Zamenhof R, Solares G, et al. A phase I dose escalation trial of 
boron neutron capture therapy for subjetcs with metastatic subcutaneous melanoma of 
the extremities. In: Mishima Y, editor. Cancer neutron capture therapy. New York and 
London: Plenum Press; 1996 p.707-16. 
 
6. Fukuda H, Honda C, Wadabayashi N, Kobayashi T,  et al. Pharmacokinetics of 10B-
p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of 














7.  Menendez P, Roth B, Pereira M, et al. BNCT for skin melanoma in extremities: 
updated argentine clinical results. Appl Rad Isot 2009;67: S50-S53. 
 
8. Pawlik T and Keyomarsi K. Role of cell cycle in mediating sensitivity to 
radiotherapy. Int J Radiation Oncol Biol Phys 2004;59: 928-942.  
 
9. Chan IS, Ginsburg GS. Personalized medicine: progress and promise. Annu Rev 
Genomics Hum Genet 2011; 12:217-244.  
 
10. Guerra L, Mordoh J, Slavutsky I, et al. Characterization of IIB-MEL-J: a new and 
highly heterogenous human melanoma cell line. Pigment Cell Research 1989;2:504-
509. 
 
11. US Department of Health and Human Services. Guide for the care and use of 
laboratories animals. Public Health Service, National Institute of Health; 1985. NIH 
Publication 86-23. 
 
12. Lee YS, Bulliard D, Zalutsky M. Therapeutic efficacy of antiglioma mesenchymal 
extracellular matrix 131 I-radiolabeled murine monoclonal antibody in a human glioma 
xenograft model. Cancer Res 1998; 48:559-565.  
 
13. Coderre J, Chanana A, Joel D, et al. Biodistribution of boronophenylalanine in 
patients with glioblastoma multiforme: boron concentration correlates with tumor 














14. Santa Cruz, G., González S, Dagrosa, A, Schwint A, et al. Dynamic infrared 
imaging for biological and medical applications in Boron neutron capture therapy.  In:  
M. Safai, J. Brown (eds.), Thermosense: Thermal Infrared Applications XXXIII, 
Proceedings of SPIE . 8013 SPIE, Bellingham, WA, 2011. 
 
15. Brandizzi D, and Cabrini RL Microspectrophotometric quantitation of 
immunohistochemical reactions by image analysis.  Acta Microscopica 2013; 22:1-3. 
 
16. Gonzalez S, Bonomi M, Santa Cruz G, et al. First BNCT treatment of a skin 
melanoma in Argentina: dosimetric analysis and clinical outcome. Appl Radiat Isot 
2004;61: 1101-1105. 
 
17. Perona M, Rodríguez C, Carpano M, et al. Improvement of the boron neutron 
capture therapy (BNCT) by the previous administration of the histone deacetylase 
inhibitor sodium butyrate for the treatment of thyroid carcinoma. Radiat Envir Biophys 
2013;52:363-73. 
 
18. Hiramatsu R, Kawabata S, Miyatake S, Kuroiwa T, Easson MW, Vicente MG. 
Application of a novel boronated porphyrin (H2OCP) as a dual sensitizer for both PDT 
and BNCT. Lasers Surg Med 2011;43:52-8.  
 
19. Sun T, Zhou Y, Xie X, et al. Selective uptake of boronophenylalanine by glioma 














20. Ferrari C, Zonta C, Cansolino L, et al. Selective uptake of p-boronophenylalanine 
by osteosarcoma cells for boron neutron capture therapy. Appl Radiat Isot 2009;67: 
S341-4. 
 
21. Song C, Appleyard V, Murray K, et al. Thermograhic assessment of tumor growth 
in mouse xenografts. Int J Cancer 2007;121:1055-1058. 
 
22. Funda DP, Houstek J, Holub M, et al. Differences in thermoregulation between 
inmunocompetent and immunodeficient hairless mice exposed to mild cold. F lia 
Microbiol 1998;43:487-489. 
 
23. Lloyd-Williams K, Handley RS. Infra-red thermometry in the diagnosis of breast 
disease. Lancet 1961;2:1378-1381. 
 
24. Rieger E, Hoffman Wellenhof R, et al. Comparison of roliferative activity as 
assessed by proliferating cell nuclear antigen (PCNA) and Ki 67 monoclonal antibodies 
in melanocityc skin lesions. J Cutan Pathol 1993;20:229-236. 
 
25. Vogt T, Zipperer K, Vogt A, et al. P53 protein and Ki 67 antigen expression are 
both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. 
Histopathology 1997; 30:57-63. 
 
26. Coderre J, Chanana A, Joel D, et al. Biodistribution of boronophenylalanine in 
patients with gioblastoma mltiforme: boron concentration correlates with tumor 














27. Eichhoff O, Zipser M, Xu M, et al. The inmunohistochemistry of invasive and 
proliferative phenotype swiching in melanoma: a case report. Melanoma Res 
2010;20:349-355. 
 
28. Kuzu I, Bicknell R, Harris A, et al. Heterogenity of vascular endothelial cells with 

















Legends of the figures 
 
Figure 1: Cellular boron uptake in the three human melanoma cell lines (A375, MEL-J 
and M8) after 0.5, 1, 2, 4 and 24 h of incubation with BPA (50 ppm 10B). After 4 h of 
incubation, the ratios MEL-J/M8 and A375/M8 were 3.40 and 2.73, respectively. Each 
point is the average of three independent experiments ± SEM. ***, P < 0.001 for MEL-
J vs. M8 and A375 vs. M8 at 24 hours. 
 
Figure 2A: Tumor temperature vs. T/B ratio, for different animals. Temperature 
measurements using SIRI were taken prior to the biodistribution studies, between one 
week and one day before. A significant correlation between tumor temperature and T/B 
boron concentration ratio was found (R-square=0.7, rational function fit). 
 
Figure 2B: Body core temperature minus tumor temperature vs. T/B ratio. Again, a 
significant correlation (R-square: 0.76, rational function fit) was observed, slightly 
better than Ttum vs. T/B. Neglecting inflammation or metabolic sources, the difference 
between body core temperature (Tcore) and tumor temperature (Ttum) represents the 
temperature drop through the tumor, which is proportional to tumor thickness and 
inversely proportional to heat conductivity. If other heat sources were present, this 
difference would always decrease and it can be even negative (tumor temperature higher 
than 37 ºC). In the present experimental set-up, it cannot be possible to uncouple both 
contributions, unless dynamic infrared studies are employed, which esentially exploit 
transient changes to determine both heat difussivity (related with the characteristic time 
for temperature recovery) and heat sources (associated with the asymptotic temperature 














Figure 3A: Hematoxylin and eosin stained tumour section. (40X). Tumor with large 
areas of viability. One representative image from 10 mice per group. 
 
Figure 3B: Hematoxylin and eosin stained tumour section. Extensive areas of necrosis 
are highlighted in the tumor section with black arrows. (40X). One representative image 
from 10 mice per group. 
 
Figure 3C: Percentage of tumor viability vs. boron uptake (ppm) in different samples. 
The tumors with large areas of viability presented high boron concentrations.  
 
Figure 4 A-D: Ki-67 and CD31 stains, each performed on histological sections of 
tumor samples of higher boron concentrations (left panel) and lower boron uptake (right 
panel) (20X). 
 
Figure 5: “Active” minimum boron concentration (i.e., the difference between 
minimum tumor boron concentration minus blood boron concentration) vs. Proliferation 
Density, PD, for different tumors. Vertical error bars represent the experimental 
uncertainty in boron measurements and horizontal error bars are the result of adding in 
quadratures the errors for cell counting (observer cell selection, set to 10% as a 
conservative estimate) and IOD standard deviation. According to the simple 
interpretation of the tumor-minus-blood difference that accounts for active BPA uptake, 
it is assumed that for very low PD values (almost no active cells) this difference should 













take place. Under these assumptions, a logistic curve was employed, with the constraint 
that it must pass through the (0,0). 
 
Table 1: Boron concentration in the different tissues of NIH nude mice bearing human 
melanoma (MEL-J). The measurements were performed at different times after BPA 
injection at a dose of 350 mg/Kg b.w. The values are the average ± SEM of 12 separate 
biodistribution studies with n = 10 mice per experimental group. **, P < 0.01; ***, P < 


















Tissue 0.5 h 1 h 2 h 3 h 
Tumor 
15.8 ± 2.3 
(5.4-24.0) 
22.3 ± 1.9** 
(13.9-28.2) 
25.9 ± 2.6*** 
(11.7-52.0) 
19.8 ± 2.5 
(3.1-33.5) 
Blood 
7.2 ± 1.2 
(4.8-9.1) 
8.8 ± 1.9 
(3.9-15.0) 
6.0 ± 1.7 
(2.2-14.0) 
3.5 ± 1.0 
(1.6-5.0) 
Distal Skin 
10.9 ± 1.6 
(7.0-15.7) 
12.2 ± 2.2 
(5.7-23.0) 
10.4 ± 2.3 
(3.7-25.0) 
8.6 ± 2.3 
(2.9-21.9) 
Surrounding Skin 
11.2 ± 2.0 
(6.5-22.6) 
15.3 ± 2.4 
(8.1-36.4) 
13.0 ± 2.3 
(3.0-23.6) 
10.9 ± 2.8 
(2.9-31.1) 
Liver 
10.4 ± 2.4 
(2.2-22.5) 
8.6 ± 1.4 
(5.9-13.5) 
6.8 ± 1.6 
(3.1-15.1) 
4.5 ± 1.3 
(2.4-7.4) 
Spleen 
14.1 ± 2.5 
(3.9-29.1) 
13.7 ± 2.0 
(8.4-24.2) 
13.4 ± 2.8 
(6.1-34.9) 
7.1 ± 2.0 
(2.9-16.6) 
Kidney 
27.3 ± 3.1 
(17.4-43.4) 
33.5 ± 2.7 
(21.5-46.9) 
17.3 ± 2.6 
(7.1-35.6) 
14.9 ± 3.3 
(6.1-48.5) 
Lung 
12.1 ± 1.9 
(3.5-16.4) 
11.3 ± 1.7 
(6.5-17.7) 
8.7 ± 2.3 
(3.1-28.7) 
6.0 ± 1.8 
(3.5-16.1) 
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